Journal Article Epublish 10 citations
PubMed: 36250098 DOI: 10.3389/fmed.2022.995069
Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19.
Front Med (Lausanne) 9:995069
Authors: Céline Occelli, Jean-Marie Guigonis, Sabine Lindenthal, Alexandre Cagnard, Fanny Graslin, Vesna Brglez, Barbara Seitz-Polski, Jean Dellamonica, Jacques Levraut, Thierry Pourcher
Affiliations
- Transporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
- Department of Emergency, University Hospital, Nice, France.
- School of Medicine, Université Côte d'Azur, Nice, France.
- Unité de Recherche Clinique Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
- Department of Immunology, University Hospital, Nice, France.
- Medical Intensive Care Unit, University Hospital, Nice, France.
Abstract
Objectives
The COVID-19 pandemic has been a serious worldwide public health crisis since 2020 and is still challenging healthcare systems. New tools for the prognosis and diagnosis of COVID-19 patients remain important issues.
Design
Here, we studied the metabolome of plasma samples of COVID-19 patients for the identification of prognosis biomarkers.
Patients
Plasma samples of eighty-six SARS-CoV-2-infected subjects and 24 healthy controls were collected during the first peak of the COVID-19 pandemic in France in 2020.
Main results
Plasma metabolome fingerprinting allowed the successful discrimination of healthy controls, mild SARS-CoV-2 subjects, and moderate and severe COVID-19 patients at hospital admission. We found a strong effect of SARS-CoV-2 infection on the plasma metabolome in mild cases. Our results revealed that plasma lipids and alterations in their saturation level are important biomarkers for the detection of the infection. We also identified deoxy-fructosyl-amino acids as new putative plasma biomarkers for SARS-CoV-2 infection and COVID-19 severity. Finally, our results highlight a key role for plasma levels of tryptophan and kynurenine in the symptoms of COVID-19 patients.
Conclusion
Our results showed that plasma metabolome profiling is an efficient tool for the diagnosis and prognosis of SARS-CoV-2 infection.
MeSH
Coronavirus, Biomarkers, Covid-19, Metabolomics, Diagnosis, Pandemics, Prognosis, Infections, Plasma
Cited by
- Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer. Cancers (Basel), 2023
- Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics. Metabolites, 2023
- Metabolomic Insights into COVID-19 Severity: A Scoping Review. Metabolites, 2024
- Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. Acta Crystallogr D Struct Biol, 2023
- N-Lactoyl Amino Acids: Emerging Biomarkers in Metabolism and Disease. Diabetes Metab Res Rev, 2025
- Assessing metal-induced glycation in French fries. Metallomics, 2025
- Advantages of Metabolomics-Based Multivariate Machine Learning to Predict Disease Severity: Example of COVID. Int J Mol Sci, 2024